EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Frequency changes in HLA‐I alleles: A marker to guide immunotherapy in lung adenocarcinoma patients and its relationship with tumor mutational burden and PD‐L1 expression

Xuanpeng Wu, Hao Wang, Fei Xue, Tao Jiang, Nanzheng Chen, Tianju Wang, Yong Zhang iD, Guangjian Zhang iD, Junke Fu, Qifei Wu iD

Thoracic Cancer · 2023

DOI: 10.1111/1759-7714.14939 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, 2023. Verfasst von Xuanpeng Wu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, HLA-A Antigens, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CSCO-Hansoh Pharma Tumor Foundation, Key Research and Development Projects of Shaanxi Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The aim of the study was to investigate differences in HLA‐I alleles between lung adenocarcinoma patients and healthy controls and determine their association with PD‐L1 expression and tumor mutational burden (TMB) to understand the mechanism underlying lung adenocarcinoma susceptibility.

Methods

Differences in HLA allele frequencies between the two groups were analyzed in a case–control study. PD‐L1 expression and TMB in lung adenocarcinoma patients were determined and their relationships with HLA‐I were analyzed.

Results

The lung adenocarcinoma group showed significantly higher HLA‐A*30:01 ( p = 0.0067, odds ratio [OR], 1.834; 95% confidence interval [CI]: 1.176–2.860), B*13:02 ( p = 0.0050, OR, 1.855; 95% CI: 1.217–2.829), and C*06:02 ( p = 0.0260, OR, 1.478; 95% CI: 1.060–2.060) and significantly lower B*51:01 ( p = 0.0290, OR, 0.6019; 95% CI: 0.3827–0.9467), and C*14:02 ( p = 0.0255, OR, 0.5089; 95% CI: 0.2781–0.9312) than the control group. Haplotype analysis results showed that HLA‐A*30:01–B*13:02 ( p = 0.0100, OR, 1.909; 95% CI: 1.182–3.085), A*11:01–C*01:02 ( p = 0.0056, OR, 1.909; 95% CI: 1.182–3.085), A*30:01–C*06:02 ( p = 0.0111, OR, 1.846; 95% CI: 1.147–2.969), and B*13:02–C*06:02 ( p = 0.0067, OR, 1.846; 95% CI: 1.147–2.969) frequencies significantly increased and B*51:01–C*14:02 ( p = 0.0219, OR, 0.490; 95% CI: 0.263–0.914) frequency significantly decreased in lung adenocarcinoma patients. Three‐locus haplotype analysis showed that HLA‐A*30:01‐B*13:02‐C*06:02 frequency ( p = 0.0100, OR, 1.909; 95% CI: 1.182–3.085) significantly increased in patients.

Conclusion

HLA‐A*30:01, B*13:02, and C*06:02 may be the susceptibility genes and HLA‐B*51:01 and C*14:01 act as the resistance genes of lung adenocarcinoma. The changes in HLA‐I allele frequencies had no association with PD‐L1 expression and TMB among these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungCarcinoma, Non-Small-Cell LungHLA-A AntigensLung NeoplasmsHumansAllelesB7-H1 AntigenBiomarkers, TumorCase-Control StudiesImmunotherapyMutation

Stichwörter der Autor:innen

PD-L1TMBallelehuman leukocyte antigenlung adenocarcinoma

Substanzen

B7-H1 AntigenBiomarkers, TumorHLA-A Antigens

Autor:innen und Institutionen

  • Department of Thoracic Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • HLA Typing Laboratory, Blood Center of the Shaanxi Province, Institute of Xi'an Blood Bank, Xi'an, China.

ORCID-Profile: Yong Zhang, Guangjian Zhang, Qifei Wu

Förderung

  • CSCO-Hansoh Pharma Tumor Foundation
  • Key Research and Development Projects of Shaanxi Province
  • National Natural Science Foundation of China

Zitieren

APA

Wu, X., Wang, H., Xue, F., Jiang, T., Chen, N., Wang, T., Zhang, Y., Zhang, G., Fu, J., & Wu, Q. (2023). Frequency changes in HLA‐I alleles: A marker to guide immunotherapy in lung adenocarcinoma patients and its relationship with tumor mutational burden and PD‐L1 expression. Thoracic Cancer. https://doi.org/10.1111/1759-7714.14939

Vancouver

Wu X, Wang H, Xue F, Jiang T, Chen N, Wang T, et al. Frequency changes in HLA‐I alleles: A marker to guide immunotherapy in lung adenocarcinoma patients and its relationship with tumor mutational burden and PD‐L1 expression. Thoracic Cancer. 2023. doi:10.1111/1759-7714.14939

BibTeX
@article{Wu2023,
  author = {Wu, Xuanpeng and Wang, Hao and Xue, Fei and Jiang, Tao and Chen, Nanzheng and Wang, Tianju and Zhang, Yong and Zhang, Guangjian and Fu, Junke and Wu, Qifei},
  title = {Frequency changes in HLA‐I alleles: A marker to guide immunotherapy in lung adenocarcinoma patients and its relationship with tumor mutational burden and PD‐L1 expression},
  journal = {Thoracic Cancer},
  year = {2023},
  doi = {10.1111/1759-7714.14939}
}
Kostenlos starten →